三诺生物
(300298)
| 流通市值：106.32亿 | | | 总市值：131.76亿 |
| 流通股本：4.55亿 | | | 总股本：5.64亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,182,048,562.89 | 2,133,039,651.44 | 1,013,580,318.64 | 4,058,786,045.41 |
| 营业收入 | 3,182,048,562.89 | 2,133,039,651.44 | 1,013,580,318.64 | 4,058,786,045.41 |
| 二、营业总成本 | 2,922,130,369.96 | 1,914,280,897.25 | 921,145,209.82 | 3,730,526,477.87 |
| 营业成本 | 1,424,691,749.88 | 956,607,859.95 | 499,413,679.89 | 1,864,682,259.15 |
| 税金及附加 | 30,718,632.18 | 21,064,901.96 | 9,526,471.37 | 40,610,098.6 |
| 销售费用 | 842,261,617.67 | 556,267,169.63 | 249,931,249.8 | 1,001,480,697.49 |
| 管理费用 | 326,824,721.7 | 204,312,632.89 | 65,828,654.51 | 418,257,904.09 |
| 研发费用 | 278,469,037.83 | 171,174,001.18 | 95,585,949.49 | 356,405,035.56 |
| 财务费用 | 19,164,610.7 | 4,854,331.64 | 859,204.76 | 49,090,482.98 |
| 其中:利息费用 | 36,500,349.65 | 24,561,181.65 | 13,003,522.58 | 66,284,974.73 |
| 其中:利息收入 | 15,488,574.73 | 9,840,674.26 | 5,433,877.12 | 17,927,995.17 |
| 加:投资收益 | -90,742.78 | 706,693.05 | 145,920.15 | 733,004.45 |
| 资产处置收益 | -6,001,488.63 | -3,053,425.35 | -2,961,669.08 | -6,004,816.23 |
| 资产减值损失(新) | -4,578,492.42 | -4,197,429.46 | -657,769.86 | -116,745,988.41 |
| 信用减值损失(新) | -22,132,977.44 | -23,853,915.9 | -5,321,404.29 | -13,403,548.76 |
| 其他收益 | 94,045,338.64 | 67,122,422.8 | 25,263,022.21 | 82,172,941.15 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 321,159,830.3 | 255,483,099.33 | 108,903,207.95 | 275,011,159.74 |
| 加:营业外收入 | -39,274.11 | 210,951.36 | 199,641.9 | 1,213,324.18 |
| 减:营业外支出 | 2,527,082.93 | 510,013.86 | 358,853.61 | 27,663,478.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 318,593,473.26 | 255,184,036.83 | 108,743,996.24 | 248,561,005.09 |
| 减:所得税费用 | 46,965,866.72 | 50,352,949.35 | 17,122,808.23 | 52,716,009.63 |
| 六、净利润 | 271,627,606.54 | 204,831,087.48 | 91,621,188.01 | 195,844,995.46 |
| 持续经营净利润 | 271,627,606.54 | 204,831,087.48 | 91,621,188.01 | 195,844,995.46 |
| 归属于母公司股东的净利润 | 255,342,147.59 | 197,485,429.08 | 80,937,582.74 | 284,397,911.89 |
| 少数股东损益 | 16,285,458.95 | 7,345,658.4 | 10,683,605.27 | -88,552,916.43 |
| (一)基本每股收益 | 0.46 | 0.36 | 0.15 | 0.51 |
| (二)稀释每股收益 | 0.46 | 0.36 | 0.15 | 0.51 |
| 八、其他综合收益 | -56,311,165.52 | -20,768,921.79 | -34,870,743.31 | 40,731,598.7 |
| 归属于母公司股东的其他综合收益 | -46,351,970.54 | -18,609,097.48 | -32,277,610.06 | 30,168,975.42 |
| 九、综合收益总额 | 215,316,441.02 | 184,062,165.69 | 56,750,444.7 | 236,576,594.16 |
| 归属于母公司股东的综合收益总额 | 208,990,177.05 | 178,876,331.6 | 48,659,972.68 | 314,566,887.31 |
| 归属于少数股东的综合收益总额 | 6,326,263.97 | 5,185,834.09 | 8,090,472.02 | -77,990,293.15 |
| 公告日期 | 2024-10-24 | 2024-08-29 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |